Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Exclusion Criteria

• •Emergence of any clinically significant condition/disease during the previous ofatumumab study in which study participation might result in safety risk for the subject
• •Subjects with active systemic bacterial, viral or fingal infections, or chronic infection (e.g. AIDS)
• •Subjects taking medications prohibited by the protocol
• •Vaccination sub-study:
• •known hypersensitivity or history of systemic allergic, neurologic or other reactions to vaccines
• •allergies to egg or shellfish
• •any safety findings including low IgG/IgM requiring ofatumumab interruption within 12 weeks prior to vaccination sub-study start
• •any major episode of infection requiring hospitalization or treatment with intravenous antibiotics within 2 weeks of the first vaccination sub-study visit